Paul G. Richardson

TL;DR: The favorable tolerability of perifosine will allow for its testing in combination with multiple targeted therapies to improve PFS and OS, which represent an important unmet need in these populations.

TL;DR: The latest progress in the development of novel anti-MM therapies are reviewed, with major focus on therapies which have translated from preclinical evaluation to clinical application, including thalidomide and its more potent immunomodulatory (IMiD) derivatives, the first-in-class proteasome inhibitor bortezomib, and arsenic trioxide.

TL;DR: This review discusses challenges in multiple myeloma, as well as potential strategies to address them, with the aim of making significant improvement in the clinical outcome of patients with MM.

TL;DR: This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan–prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP) and serum Dickkopf‐1 (DKK‐1), an inhibitor of osteoblast differentiation, during treatment.

TL;DR: This review focuses on results from key phase II and III trials of bortezomib, thalidomides, and lenalidomide alone or in combination, and their emerging role in improving outcomes.